CCCC C4 Therapeutics, Inc.: institutional ownership and insider trading
154 funds reported holding $559M of C4 Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $158M, with 51 new positions and 27 funds selling out; over the last 12 months insiders bought $0 and sold $22.2K on the open market.
Famous investors holding CCCC
- Two Sigma (Two Sigma Investments): $16.2M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $5.56M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $20.0M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $8.13M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $1.01M, 0.0% of the portfolio
Largest institutional holders of CCCC
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $41.4M
- RA CAPITAL MANAGEMENT, L.P. — $37.4M
- BlackRock, Inc. (BLK) — $36.9M
- Squadron Capital Management LLC — $35.5M
- Lynx1 Capital Management LP — $34.2M
- Bain Capital Life Sciences Investors, LLC — $33.5M
- JPMORGAN CHASE & CO (JPM, AMJB, VYLD, JPM-PC, JPM-PD, JPM-PJ, JPM-PK, JPM-PL, JPM-PM) — $20.7M
- VANGUARD CAPITAL MANAGEMENT LLC — $20.6M
- CITADEL ADVISORS LLC — $20.0M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $16.5M
Recent CCCC insider trades
- Jan 16, 2026: Reyno Leonard sold 10,000 shares ($22.2K)
- Feb 18, 2025: Boyle Scott N sold 1,159 shares ($3.65K)
5%+ owners
- Lynx1 Capital Management LP: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- RA Capital Management, L.P.: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Sirenia Capital Management LP: 9.9% (Schedule 13G, filed May 15, 2026)
- Morgan Stanley: 8.0% (Schedule 13G/A, filed Aug 12, 2026)
- Squadron Master Fund LP: 6.9% (Schedule 13G/A, filed Aug 14, 2026)
- BlackRock, Inc.: 6.9% (Schedule 13G, filed Jul 27, 2026)